8,081 trials (keyword fallback)
Graves Disease
Primary: Occurrence of Treatment Emergent Adverse Events (TEAE), Serious Adverse Events (SAE), and Laboratory Abnormalities up to Week 22 Compared to Baseline. — 311; 293; 18; 0…
Thyroid-associated Ophthalmopathy
Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73
Graves Disease
Primary: CD80 Level — 45.60; 54.51 nM — p=0.48
Graves Disease · Hyperthyroidism
Primary: Blood Loss During Surgery — 61.67; 161.67 mL
Graves' Disease
Primary: Dosimetry Studies
Graves' Disease
Primary: Percentage of Participants Whose Thyroid Stimulating Hormone (TSH) Levels Normalize After 12 Week Treatment — 0 percentage of participants
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
Graves Ophthalmopathy
Primary: Percent Change Lumbar Spine Bone Mineral Density — 1.37 Percentage change
Thyroid Eye Disease · Graves' Orbitopathy
Primary: Percentage of Participants Who Were Proptosis Responders at Week 24 — 9.5; 82.9 percentage of participants — p=<0.001
Ophthalmopathy, Thyroid-Associated
Primary: Clinical Activity Score (a Composite Measure of Ophthalmological Signs and Symptoms) — 4.25; 2.77; 4.25; 4.20 score on a scale
Thyroid Eye Disease
Primary: Percentage of Participants With a ≥ 2 mm Reduction From Baseline in the Study Eye Without Deterioration of Proptosis in the Fellow Eye at Week 24 — 89.2; 53.8 percentage…
Graves' Disease
Primary: Number of Participants With Overt Hypothyroidism — 11; 17 Participants — p=0.23
Chronic Kidney Disease
Primary: Whole Blood Platelet Aggregation to 0.5 Millimoles Arachidonic Acid — 21.0; 18.0; 0; 0 ohms
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Chagas Disease
Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects